Patient P-01716

Synthetic patientNBL-101 · Day 114 · 45–54 · M · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Unstable

Discontinuation risk

81%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 54 GI-04 recommended — GI Support Protocol GI-04
Day 55 Patient accepted — Started GI-04 in the companion
Day 63 GI symptom burden −19% vs expected — GI Support Protocol GI-04
Day 69 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 50.

Primary contributors, last 14 days

Nutritional resilience-9
GI instability+7
Inflammatory activity+7
Toxicity+7
Treatment adherence-4

What helped?

GI Support Protocol GI-04Day 54
Result: symptom burden −19%

LIFE OS recommendation

Dietary Support Protocol NP-02

65%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 56 and rising
- WearableSleep 6.0 h, below personal baseline
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 53
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 41/100
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 56
Autonomic recovery ↑20
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 2.6 · butyrate capacity 41/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 44 ms
Sleep: 6.1 h
Steps: 7,146
Resting HR: 68 bpm

Daily log: GI score 56, nutritional resilience 39, adherence 44.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01339	50%	S14	GI-04	improved	54
P-01842	50%	S14	NP-02	improved	55
P-01831	49%	S15	SC-12	improved	49
P-01365	48%	S14	SC-12	improved	49
P-01473	48%	S14	GI-04	improved	51
P-01707	48%	S14	GI-04	improved	57
P-01311	47%	S14	ME-01	improved	49
P-01465	47%	S14	NP-02	improved	56
P-01720	47%	S14	NP-02	improved	47
P-01389	46%	S14	SC-12	improved	46
P-01581	45%	S18	GI-04	improved	51
P-01751	45%	S14	ME-01	improved	48